ch.oddb.org
 
Apotheken | Hôpital | Interactions | LiMA | Médecin | Médicaments | Services | T. de l'Autorisation
GlaxoSmithKline AG - Infanrix DTPa-IPV+Hib, Pulver und Suspension zur Herstellung einer Injektionssuspension
0061901
Infanrix DTPa-IPV+HibPulver und Suspension zur Herstellung einer Injektionssuspension
J07CA06Diphtherie-Haemophilus-influenzae B-Pertussis-Poliomyelitis-Tetanus
29.09.1998  
Composition
I) DTPa-IPV: toxoidum diphtheriae min. 30 U.I., toxoidum tetani min. 40 U.I., toxoidum pertussis 25 µg, haemagglutininum filamentosum (B. pertussis) 25 µg, pertactinum (B. pertussis) 8 µg, virus poliomyelitis typus 1 inactivatus (Stamm Mahoney) 40 U., virus poliomyelitis typus 2 inactivatus (Stamm MEF-1) 8 U., virus poliomyelitis typus 3 inactivatus (Stamm Saukett) 32 U., aluminium 0.5 mg ut aluminii hydroxidum hydricum ad adsorptionem, natrii chloridum corresp. natrium 1.8 mg, medium 199, aqua ad iniectabile ad suspensionem pro 0.5 ml, residui: neomycini sulfas, polymyxini B sulfas, polysorbatum 80, formaldehydum. II) Hib: polysaccharida haemophili influenzae typus B 20752 conjugata cum toxoido tetani 10 µg, lactosum, pro praeparatione. I) et II) corresp. DTPa-IPV + Hib: toxoidum diphtheriae min. 30 U.I., toxoidum tetani min. 40 U.I., toxoidum pertussis 25 µg, haemagglutininum filamentosum (B. pertussis) 25 µg, pertactinum (B. pertussis) 8 µg, virus poliomyelitis typus 1 inactivatus (Stamm Mahoney) 40 U., virus poliomyelitis typus 2 inactivatus (Stamm MEF-1) 8 U., virus poliomyelitis typus 3 inactivatus (Stamm Saukett) 32 U., polysaccharida haemophili influenzae typus B 20752 conjugata cum toxoido tetani 10 µg, aluminium 0.5 mg ut aluminii hydroxidum hydricum ad adsorptionem, natrii chloridum corresp. natrium 1.8 mg, medium 199, lactosum, aqua ad iniectabile ad suspensionem pro 0.5 ml, residui: neomycini sulfas, polymyxini B sulfas, polysorbatum 80, formaldehydum.
Packungsbestandteile
II
 
Suspension injectable 
  
  
BAG: Principe actifConcentr.
 25 mcg
 10 mcg
 8 mcg
  
 25 mcg
  
 40 UI
 8 UI
 32 UI
 
Agents auxilliairesConcentr.
 10 µg
  
 20752
 
I) et II) corresp. DTPa-IPV + Hib: toxoidum diphtheriae min. 30 U.I., toxoidum tetani min. 40 U.I., toxoidum pertussis 25 µg, haemagglutininum filamentosum (B. pertussis) 25 µg, pertactinum (B. pertussis) 8 µg, virus poliomyelitis typus 1 inactivatus (Stamm Mahoney) 40 U., virus poliomyelitis typus 2 inactivatus (Stamm MEF-1) 8 U., virus poliomyelitis typus 3 inactivatus (Stamm Saukett) 32 U., polysaccharida haemophili influenzae typus B 20752 conjugata cum toxoido tetani 10 µg, aluminium ut aluminii hydroxidum hydricum ad adsorptionem, natrii chloridum, lactosum, medium 199, residui: polysorbatum 80 et formaldehydum et neomycini sulfas et polymyxini B sulfas, aqua q.s. ad suspensionem pro 0.5 ml 
  
BAG: Principe actifConcentr.
 25 mcg
 10 mcg
 8 mcg
  
 25 mcg
  
 40 UI
 8 UI
 32 UI
I
 
  
  
 
Principe actifConcentr.
 25µg / 0.5ml
 8µg / 0.5ml
 30U.I. / 0.5ml
 25µg / 0.5ml
 40U.I. / 0.5ml
 40U. / 0.5ml
 8U. / 0.5ml
 32U. / 0.5ml
BAG: Principe actifConcentr.
 25 mcg
 10 mcg
 8 mcg
  
 25 mcg
  
 40 UI
 8 UI
 32 UI
 
Agents auxilliairesConcentr.
Alumine0.5mg / 0.5ml
 199
Sodium Chlorure 
Neomycine Sulfate 
Polymyxine b Sulfate 
 
numéro d'emballage Taille des présentationsPEFPPCat.LSHors commerce (MedRef)
003 34.3253.75BLSNon
2025 ©ywesee GmbH
Einstellungen | Aide | FAQ | Identification | Contact | Home